Menu Search
Equities

Microport Cardioflow Medtech Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
72X:FRA

Microport Cardioflow Medtech Corp

Actions
  • Price (EUR)0.0795
  • Today's Change-0.002 / -2.45%
  • Shares traded2.27k
  • 1 Year change-9.14%
  • Beta1.0034
Data delayed at least 15 minutes, as of Feb 06 2026 07:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Microport Cardioflow Medtech Corp is a medical device company primarily engaged in the provision of total solutions to physicians and patients for the treatment of structural heart diseases. The Company’s main business is engaged in the research and development and commercialization of transcatheter and surgical solutions for structural heart diseases. The Company’s pipelines include transcatheter aortic heart valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) product, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products and procedural accessories. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)413.63m
  • Net income in HKD5.46m
  • Incorporated2019
  • Employees417.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.